Can you please explain the math behind your $25M.
Post# of 7769
Posted On: 09/25/2013 9:36:27 AM
Re: celtics2014 #226
Can you please explain the math behind your $25M. My calculations provided in a previous post indicated they need to sell roughly 140,000,000 tablets in 2014 to reach $25M in revenue:
"Do you have any information in regards to how you back into your $25M revenue projection? I know the company is required to order 10,000,000 of the 80mg tablets and 10,000,000 of the 160mg tablets in year 1. In year 2 they need to order 16,500,000 of both the 80mg and 160mg tablets to maintain exclusivity of Rapimeds tech.
I can buy genereic OTC Aceteminophen childrens tablets without Rapimed technology for $4.00 for a 30 pack. 20,000,000 tablets total in 2014 at say $5.00(includes Rapimed tech) for a box of 30 would equal 666,666 packages sold * $5 = $3,333,333 revenue on 20,000,000 tablets. ScripsAmerica would need to sell 140,000,000 tablets in 2014 to reach your $25M target revenue."
Correct me if my math is wrong. Appreciate all the help.
Still a believer but would appreciate another opinion behind the math of Rapimeds.
JR
"Do you have any information in regards to how you back into your $25M revenue projection? I know the company is required to order 10,000,000 of the 80mg tablets and 10,000,000 of the 160mg tablets in year 1. In year 2 they need to order 16,500,000 of both the 80mg and 160mg tablets to maintain exclusivity of Rapimeds tech.
I can buy genereic OTC Aceteminophen childrens tablets without Rapimed technology for $4.00 for a 30 pack. 20,000,000 tablets total in 2014 at say $5.00(includes Rapimed tech) for a box of 30 would equal 666,666 packages sold * $5 = $3,333,333 revenue on 20,000,000 tablets. ScripsAmerica would need to sell 140,000,000 tablets in 2014 to reach your $25M target revenue."
Correct me if my math is wrong. Appreciate all the help.
Still a believer but would appreciate another opinion behind the math of Rapimeds.
JR
(0)
(0)ScripsAmerica Inc (SCRC) Stock Research Links
Scroll down for more posts ▼